Longevity & Aging
a bempedoic-acid prodrug (via PPAR-alpha activation) decreases amyloidogenic APP processing
In plain terms: Could the cholesterol drug bempedoic acid, by switching on PPAR-alpha, steer the brain away from making Alzheimer's amyloid?
Part of: 💊 bempedoic acid
Independent mouse and mechanistic work consistently shows PPAR-alpha activation — which bempedoic acid does (Cell Metab 2026) — can steer APP away from the amyloid pathway and boost amyloid clearance, and that pathway evidence is what carries the grade. But no study tests bempedoic acid itself in the brain, so this is a mechanism/animal-grade inference about a plausible repurposing, NOT a demonstrated anti-amyloid effect in people.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
Independent mouse and mechanistic work consistently shows PPAR-alpha activation, which bempedoic acid produces, shifting amyloid precursor processing toward the non-amyloidogenic route and enhancing clearance. It is entirely preclinical: no human study tests whether bempedoic acid does this in people, and one cell study found PPAR-alpha agonists failing on part of the pathway.
The evidence (8)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Combs CK, Bates P, Karlo JC, Landreth GE 2001 · J Neurosci | in-vitro | mixed | moderate | PPARalpha agonists suppress Abeta-stimulated proinflammatory gene expression in monocytes but fail to block neurotoxic-factor release. |
| Raha S, Ghosh A, Dutta D, Patel DR, Pahan K 2021 · Sci Signal | animal | supports | moderate | PPARalpha activation enhances astroglial LDLR/TFEB-mediated uptake and lysosomal degradation of Abeta, lowering brain amyloid burden in 5XFAD mice. |
| Luo R, Su LY, Li G, Yang J, Liu Q, Yang LX, Zhang DF, Zhou H, Xu M, Fan Y, Li J, Yao YG 2020 · Autophagy | animal | supports | moderate | PPARalpha agonists (gemfibrozil, Wy14643) induce autophagy and reduce soluble/insoluble Abeta and cognitive deficits in APP-PSEN1 mice. |
| Corbett GT, Gonzalez FJ, Pahan K 2015 · Proc Natl Acad Sci U S A | animal | supports | high | Independent mechanism: PPARalpha activation stimulates ADAM10-mediated alpha-secretase cleavage of APP (non-amyloidogenic), reducing Abeta in mice. Supports pathway plausibility, not bempedoic specifically. |
| Li Y, Zhang Y, Wang Q, Wu C, Du G, Zeng Y, Song Z, Jiang X, Jiang X, Zhuo R, Li J 2024 · Neurol Res | animal | supports | low | PPARalpha/gamma dual agonist attenuates AD molecular pathology in model; supportive of class effect, not bempedoic. |
| Rangasamy SB, Jana M, Dasarathi S, Kundu M, Pahan K 2023 · Brain Behav Immun | animal | supports | moderate | Exercise activates hippocampal PPARalpha -> upregulates ADAM10, decreases plaques & improves cognition in AD mice; corroborates PPARalpha->ADAM10->non-amyloidogenic axis. |
| Comerota MM, Gedam M, Xiong W, Jin F, Deng L, Wang MC, Wang J, Zheng H 2023 · Mol Neurodegener | animal | contradicts | moderate | 5xFAD mice, 8 weeks of the OEA analog KDS-5104 (10 mg/kg i.p., 3x/week, n=5-6/group): Abeta plaque number and 6E10 area fell, but the claim's own mechanism tested null — 'we examined levels of full-length APP, its C-terminal fragments (APP-CTF), and ADAM10 by Western blotting. We observed no appreciable differences between KDS-5104 and vehicle treated 5xFAD'; the authors conclude 'the reduction in Abeta pathology is unlikely due to changes in APP expression or processing'. The Abeta drop was attributed to microglial uptake and lysosomal clearance, not to a shift in APP processing. |
| Papa C, Rose A, Martin HNG, Useini A, Geier F, Liao L, Rodríguez-Aguilera JR, Valina-Allo P, Hoffmann A, Tvardovskiy A, Zulfqar F, Zimmerman A, Schicht G, Ott F, Körner C, Engelmann B, Rolle-Kampczyk U, von Bergen M, Meier M, Bartke T, Seehofer D, Klöting N, Matz-Soja M, Damm G, Boeckel JN, Buescher JM, Blüher M, Laufs U, Bondareva O, Sträter N, Künze G, Heiker JT, Sheikh BN 2026 · Cell Metab | mechanism | mixed | high | Verified cited paper: bempedoic acid directly binds & activates PPARalpha (X-ray + hepatocyte/liver FAO). Confirms PPARalpha activation ONLY; paper is about hepatic fatty-acid oxidation, NOT APP/amyloid. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.